Takeda Pharmaceutical Company Ltd News - TAK | Aktien New York Börse

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June...

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable Growth Expected Phase 3 Data Readouts in 2025...

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval...

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone...

Takeda gibt starke Ergebnisse für das erste Halbjahr des Geschäftsjahres 2024 bekannt und erhöht den Ausblick für das Gesamtjahr

Umsatzwachstum von +13,4 % zu aktuellen Wechselkursen (AER); +5,0 % zu konstanten Wechselkursen (CER) Getrieben durch die kontinuierliche...

Takeda annonce de solides résultats pour le premier semestre de l’exercice 2024 et revoit à la hausse ses perspectives pour l’ensemble de l’année

Croissance du chiffre d’affaires de +13,4 % à taux de change réels (TCR) ; +5,0 % à taux de change constants (TCC) grâce à la progression...

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

武田薬品工業: 2024年度上期の好調な業績を公表 - 通期の見通しを上方修正

売上収益は、実勢レート（AER：Actual Exchange Rate）ベースで対前年同期+13.4%、恒常為替レート（CER：Constant Exchange Rate）ベースで同+5.0%成長し、...

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Revenue Growth of +13.4% at Actual Exchange Rates (AER); +5.0% at Constant Exchange Rate (CER) Driven by Continued Advancement of Growth &...

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

First-of-its-Kind Research Collaboration for Takeda and Boston Medical Center with the Aim to Decarbonize the Health Care Value Chain Three-Year...

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in Japan...

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

− Presentations Include New Data from the TAK-861-2001 Phase 2b Trial in Narcolepsy Type 1 Highlighting Impact on Daily Functioning Including...

Takeda s'engage à verser plus de 32 millions de dollars dans le cadre de cinq nouveaux partenariats internationaux en faveur de la responsabilité sociale des entreprises (RSE), afin de renforcer sa contribution à la santé au sein de 93 pays

Plus de 22 000 employés de Takeda ont sélectionné les nouveaux partenaires pour l'exercice 2024 : Population Services International, Bulungula...

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Takeda Pharmaceutical Company Ltd (TAK)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

TAK Nachrichten

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

Takeda gibt starke Ergebnisse für das erste Halbjahr des Geschäftsjahres 2024 bekannt und erhöht den Ausblick für das Gesamtjahr

Takeda annonce de solides résultats pour le premier semestre de l’exercice 2024 et revoit à la hausse ses perspectives pour l’ensemble de l’année

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

武田薬品工業: 2024年度上期の好調な業績を公表 - 通期の見通しを上方修正

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Takeda s'engage à verser plus de 32 millions de dollars dans le cadre de cinq nouveaux partenariats internationaux en faveur de la responsabilité sociale des entreprises (RSE), afin de renforcer sa contribution à la santé au sein de 93 pays

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Takeda Pharmaceutical Company Ltd (TAK) News

Takeda Pharmaceutical Company Ltd (TAK)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

TAK Nachrichten

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

Takeda gibt starke Ergebnisse für das erste Halbjahr des Geschäftsjahres 2024 bekannt und erhöht den Ausblick für das Gesamtjahr

Takeda annonce de solides résultats pour le premier semestre de l’exercice 2024 et revoit à la hausse ses perspectives pour l’ensemble de l’année

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

武田薬品工業: 2024年度上期の好調な業績を公表 - 通期の見通しを上方修正

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Takeda s'engage à verser plus de 32 millions de dollars dans le cadre de cinq nouveaux partenariats internationaux en faveur de la responsabilité sociale des entreprises (RSE), afin de renforcer sa contribution à la santé au sein de 93 pays

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen